|This Slide: #19 of 100|
Slide #19. Bristol-Myers Squibb — iPierian, Inc.
Bristol-Myers Squibb (NYSE:BMY)
Bristol-Myers Squibb Company (NYSE:BMY) and iPierian, Inc. announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Co.'s products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Co. manufactures products in the U.S., Puerto Rico and in four foreign countries. Co. has products in the following therapeutic classes: oncology; cardiovascular; and immunoscience. Co.'s products include: Opdivo; Eliquis; Orencia; Sprycel; Yervoy; Empliciti; Baraclude; the Reyataz Franchise; the Sustiva Franchise; and the Hepatitis C Franchise.
Bristol-Myers Squibb SEC Filing Email Alerts Service
Open the BMY Page at The Online Investor »
Buy (3.23 out of 4)
(ranked lower than approx. 51% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite